Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin: 2021-2025

Historic EBITDA Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 10.14%.

  • Kiniksa Pharmaceuticals International's EBITDA Margin rose 2137.00% to 10.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.99%, marking a year-over-year increase of 836.00%. This contributed to the annual value of -10.25% for FY2024, which is 1544.00% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's EBITDA Margin is 10.14%, which was down 11.42% from 11.44% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin peaked at 226.07% during Q3 2022, and registered a low of -253.13% during Q3 2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's EBITDA Margin had a median value of -3.67% in 2024 and averaged -1.05%.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's EBITDA Margin skyrocketed by 47,920bps in 2022 and then crashed by 24,675bps in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBITDA Margin (Quarterly) stood at -193.94% in 2021, then skyrocketed by 19,085bps to -3.09% in 2022, then skyrocketed by 3,336bps to 30.27% in 2023, then slumped by 3,762bps to -7.35% in 2024, then skyrocketed by 2,137bps to 10.14% in 2025.
  • Its EBITDA Margin stands at 10.14% for Q3 2025, versus 11.44% for Q2 2025 and 6.20% for Q1 2025.